More on MRK

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+52.9% Growth)
- Ratings (5.8 Score)
- Holders
- Dividends (3% Yield)
- Event Driven Deals
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (7/29/22 *Est.)
- M&A (6/30/19 *Est)
- M&A (6/30/21 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Merck (NY:MRK)
Delayed: 93.13 +1.13 (1.23%)
Prev. Close $92.00  
Open$93.25 
52 Wk High$65.46 
52 Wk Low$47.97 
Day High$93.79 
Day Low$91.70 
P/E 63.35  
EPS$1.47 
Volume25,247,926 

Friends, Peers and Foes (?): XLRN, OGN, MKKGY, 0O14, PFE (more...)

Jun 24, 2022 07:09 AM Merck (MRK), Seagen (SGEN) Takeover Talks Heat Up - WSJ
Jun 24, 2022 06:45 AM Merck (MRK) Announces EU Approval of KEYTRUDA as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection
Jun 24, 2022 06:45 AM European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
Jun 23, 2022 08:59 PM Merck (MRK) Pushes Forward with Potential Seagen (SGEN) Deal - WSJ
Jun 23, 2022 09:00 AM MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical Cancer Therapies
Jun 23, 2022 05:57 AM Merck (MRK) Announces CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of VAXNEUVANCE as an Option for Pneumococcal Vaccination in Infants and Children
Jun 22, 2022 06:28 PM CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
Jun 22, 2022 06:46 AM Merck (MRK) Announces FDA Approval of VAXNEUVANCE for Prevention of Invasive Pneumococcal Disease in Infants and Children
Jun 22, 2022 06:45 AM U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
Jun 21, 2022 04:30 PM Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
View All Articles